Martinez-Lopez, JSanchez-Vega, BBarrio, SCuenca, IRuiz-Heredia, YAlonso, RRapado, IMarin, CCedena, M-TPaiva, BPuig, NMateos, M-VAyala, RHernandez, M-TJimenez, CRosinol, LMartinez, RTeruel, Ana IsabelGutierrez, NMartin-Ramos, Maria-LuisaOriol, ABargay Lleonart, JoanBlade, JSan-Miguel, JGarcia-Sanz, RLahuerta, J-J2024-07-112024-07-112017-06Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, et al. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma [letter]. Leukemia. 2017 Jun;31(6):1446-9. Epub 2017 Feb 17.0887-6924http://hdl.handle.net/20.500.13003/10944http://hdl.handle.net/20.500.12105/20381enghttp://creativecommons.org/licenses/by-nc-nd/4.0/AgedMaleMonitoring, PhysiologicMultiple MyelomaNeoplasm, ResidualFemaleHigh-Throughput Nucleotide SequencingHumansSurvival AnalysisAntineoplastic Combined Chemotherapy ProtocolsAnalytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaletter to the editorAttribution-NonCommercial-NoDerivatives 4.0 International282100023161446-144910.1038/leu.2017.581476-5551Leukemiaopen accessHumanosProtocolos de Quimioterapia Combinada AntineoplásicaAnálisis de SupervivenciaAncianoMonitoreo FisiológicoMieloma MúltipleFemeninoSecuenciación de Nucleótidos de Alto RendimientoNeoplasia ResidualMasculino2-s2.0-85014659967402832700025L614736600